 |
|
|
| |
SUBGROUP ANALYSIS OF PATIENT-REPORTED OUTCOMES AMONG
PARTICIPANTS IN 2 PHASE III CLINICAL TRIALS OF LONG-ACTING
CABOTEGRAVIR AND RILPIVIRINE (ATLAS AND FLAIR)
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Vasiliki Chounta,1 Sterling Wu,2 Ojesh Upadhyay,2 Sandy Griffith,3 Conn Harrington,3 Chloe Orkin,4 Susan Swindells,5 William Spreen,3 David Margolis3
1ViiV Healthcare, Brentford, UK; 2GlaxoSmithKline, Collegeville, PA, USA; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4Queen Mary University, London, UK; 5University of Nebraska Medical Center, Omaha, NE, USA
|
| |
|
|
|
|
|
